O ne of the unfortunate side consequences of evidencebased medicine (EBM) is that sometimes there is no escaping how small the benefit of any individual treatment may seem. In the "days of the giants," doctors saved lives; now we can consult league tables that bloodlessly inform us how many patients-10, 50, or 200 -must receive a treatment to avert even a single bad outcome, 1 EBM's venerable number needed to treat.
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The number needed to treat is, of course, based only on average treatment effects. A limitation of EBM is that we study groups of patients, whereas we treat individuals. This mismatch can be partially addressed by the use of statistical models to calculate the important risks that determine a more "personalized" probability of benefit. When this is done, it turns out, the degree of benefit for an intervention in any typical patient is often even less than the overall average. 2 This is because benefits are determined by the baseline risk, which is usually highly skewed, such that a few high-risk patients may account for most of the benefit, whereas most patients have baseline risks (and therefore potential benefit) considerably less than the average. 3 This is true particularly when the overall risk of the outcome of interest is low because there is a lower bound for risk at 0%, creating a "floor effect."
In this issue of Circulation: Cardiovascular Quality and Outcomes, Sussman et al 4 describe the "personalized" risks and benefits of aspirin therapy for primary prevention of cardiovascular diseases, a rather extreme exemplar of the pattern described above. The number needed to treat to prevent a single ischemic event for any typical patient in a primary prevention population can easily exceed 1000 per year but may vary substantially, depending on individualized risk.
Because the benefits of aspirin are small in the primary prevention setting, and the risks of bleeding are nonnegligible-especially for older patients who have the most to gain-not only do individual benefits vary depending on personalized risks of cardiovascular disease (CVD) and personalized risk of bleeding, but, the authors show, that what constitutes a rational decision for most patients (ie, maximizes utility) is highly sensitive to patient preferences. Their main finding is that for many patients, the potential net benefit for primary prevention is so small that they should not bother to take an aspirin if aspirin-taking is, to them, a bother. Only about one-third of patients between ages 35 and 80 years, eligible for primary prevention, seem likely to obtain sufficient benefit to warrant the therapy, when taking an aspirin has a disutility of 1%.
It is widely recognized that the benefits of aspirin for primary prevention are dependent on a patient's baseline risk of CVD, and the major guidelines have incorporated risk estimation in a way that is broadly consistent with the analysis presented by Sussman et al. 5, 6 However, because Sussman et al explicitly consider that aspirin-taking might be associated with some variable patient-specific disutility independent of bleeding complications, their main conclusion is that a single threshold is inappropriate. Rather, to decide on whether or not a patient should take an aspirin requires a robust discussion of its benefits and harms, including not only individualized risk assessment for CVD and for major bleeding complications but also the elicitation of patient preferences.
The idea that patients should be involved in their medical decisions may not seem radical. However, clinicians often find the prospect of involving patients in shared decisionmaking during a short primary care visit daunting. The clinicians are often challenged in their ability both to readily estimate risk and to discuss probabilities with patients. To overcome this, risk calculators have been developed to estimate individualized risk in real time (including several different calculators for CVD risk [7] [8] [9] . The information can then be used in decision aids-electronic or paper-basedthat help communicate the individualized risks and benefits in a clear way that permits the patient to make an informed decision. A key component in this paradigm is the willingness of both patients and clinicians to actively engage in the conversation, for the patients to express their preferences, and for the clinician to respect them. Previous studies of shared decision-making using personalized risk have shown that involving patients improves knowledge, medication adherence, and satisfaction. 10, 11 The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. Recent literature suggests that using graphical displays and natural frequencies that show the population and how many will be affected and not affected by the outcome with and without treatment is a successful method of risk communication. 12, 13 These methods reduce the impact of framing, whereas graphs that show only the numerator appear to inflate the perceived risk and may induce risk-averse behavior. For example, the Figure shows how a graphical display using natural frequencies might be presented to patients with a 10-year cardiovascular risk of 10%. The decision aid to present the benefits of aspirin can also be used to present the risk of aspirin from bleeding. Thus, patients can weigh the tradeoffs and make an informed decision.
In this case, the clinician can present the information as follows: "Of 1000 people like you, 100 will and 900 will not experience a heart attack in the next 10 years and about 7 will have a stomach bleed. If all 1000 decided to take aspirin, those 900 not destined to have a heart attack will not get one; 18 of those 100 destined to have a heart attack will now avoid one thanks to the aspirin, and 82 will experience a heart attack in the next 10 years, despite using aspirin regularly; also now 10 will have a stomach bleed, 3 of which occur because of the aspirin."
This framing allows the patients to consider the absolute risks and benefits of initiating aspirin, deliberate, and come to a shared decision with their provider that best reflects their values and preferences.
Back in the real world, the prospects for such shared decision-making do not seem especially bright, given past performance. Patients are often misinformed about the risks and benefits of therapy and, in particular, often grossly overestimate the benefits of treatments. 14 -17 For example, among patients undergoing percutaneous coronary intervention for nonacute coronary artery disease, the vast majority of patients are convinced that the procedure is likely to save their life or prevent a heart attack, 18 despite evidence that it does not. 19 If patients are so ill-informed about a major medical procedure that requires signed informed consent, then what hope do we have about the even more common decisions made in the primary care setting, such as whether to take a baby aspirin?
Consider, too, what the incentives are. Previous work has shown that incorporating decision aids within a routine clinical encounter increases the visit length by about 3 to 4 minutes. 20 Although this has also been shown to lead to a more satisfying encounter for both the patient and the physician, 10,21 such nonreimbursable discussions over routine medical decisions would clearly hamper throughput. Indeed, physicians may have a financial stake in having misinformed patients who systematically overestimate treatment benefits. This is obviously true for invasive procedures such as percutaneous coronary intervention, in which better-informed patients might more frequently opt for medical management, but it is also true when quality measures reward low-benefit treatments that a fully informed and wholly rational patient might just as well decide to forgo. For many patients in whom the individualized risks and benefits of a therapy are similar, quality indicators based on overall population-wide benefits that measure the proportion of patients on a given therapy can incentivize either excluding the patient from decision-making altogether or engaging in arm-twisting rather than the deliberative process described above. 
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Although EBM may seem designed to move the practice of medicine away from the caprice of physician judgment to the unambiguous authority of data, for many clinical decisions the data unambiguously tell us that there is no clearly best decision, and it turns out that the ultimate authority is-by necessity-often the patients themselves; that is, particularly when benefits are small (or the balance of risk and benefits is highly dependent on optimal adherence), the main determinants of the best clinical decision are the values and preferences of the patient considered in the presence of adequate knowledge transfer. Moving away from population-based results to individualized decision-making requires a change in culture and a change in clinician incentives, including the development of performance measures that encourage shared decision-making. In doing so, it is critical to recognize that for many decisions-for example, whether a 47-year-old woman should get a mammogram, whether an 80-year-old man with a Hgb A1C of 8.2 should be prescribed an additional agent, whether a 77-year-old man without risk factors who had a second colonoscopy 10 years ago should get a third colonoscopy, and whether a patient should take an aspirin for primary prevention-the evidence tells us that the actual outcome of the conversation may be less important than the quality of the discussion.
Sources of Funding
This work was partially funded by grants UL1 RR025752 and R01 NS062153, both from the National Institutes of Health.
Disclosures
None.
